| Catalog No. | HY196036 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P08581 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | ABBV-399, ABT-700-vcMMAE, ABT-700, hz224G11, 1781223-80-0 |
|---|
| Background | Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic.
• MET-dependent solid tumours - molecular diagnosis and targeted therapy., PMID:32514147
• ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., PMID:27573171
• Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis., PMID:34848680
• The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance., PMID:30786811
• The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions., PMID:26822708
• MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas., PMID:34667077
• Targeting HGF/c-MET Axis in Pancreatic Cancer., PMID:33271944
• Targeting the hepatocyte growth factor/Met pathway in cancer., PMID:28673936
• Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases., PMID:30658428
• Hepatocyte growth factor in physiology and infectious diseases., PMID:28094206
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
